Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research



Fluoroquinolones resistance among uropathogens at a tertiary-care hospital, Ahmedabad

Anirudh Gupta, Bimal Chauhan, Jayshree Pethani, Parul Shah.

Abstract
Background: Urinary tract infection (UTI) is one of the most common infections in both outpatients and hospitalized patients. The progressive increase in antimicrobial resistance among patients with UTIs is of great concern.

Objective: To determine the resistance patterns of fluoroquinolones in UTIs.

Materials and Methods: This study was conducted at NHL Municipal Medical College, Ahmedabad, Gujarat, India, from October, 2013 to March, 2015. A retrospective analysis of data taken from all urine samples (6,545 patients suspected of UTI) was analyzed. A total of 1,744 isolates were found for which fluoroquinolones susceptibility was analyzed. Cultures with Candida growth were excluded from this analysis. Antimicrobial susceptibility was done by Kirby–Bauer’s disc diffusion method as per Clinical and Laboratory Standards Institute guidelines.

Result: Escherichia coli (55.1%) was the leading uropathogen, followed by Klebsiella spp. (22.3%), Pseudomonas aeruginosa (11.9%), Acinetobacter spp. (3.2%), Enterobacter spp. (2.3%), Citrobacter spp. (1.3%), Enterococcus spp. (1.2%), Proteus mirabilis (1.0%), and others (1.7%). Overall resistance to ciprofloxacin (85.5%) when compared with levofloxacin (53.8%) was higher. The levofloxacin resistance increased minimally from 55.6% overall in October 2013–March 2014 to 55.8% in October 2014–March 2015, whereas resistance to ciprofloxacin increased from 79.5% overall in October 2013–March 2014 to 90.3% in October 2014–March 2015.

Conclusion: Levofloxacin is still active against major pathogenic organisms, whereas ciprofloxacin has become largely inactive. So, it is time to reconsider the use of fluoroquinolones and develop clear strategies to counteract the development of further resistance.

Key words: Fluoroquinolones, urinary tract infection, antimicrobial resistance



Similar Articles

Insufficient ventilation led to a probable long-range airborne transmission of SARS-CoV-2 on two buses.
Ou C, Hu S, Luo K, Yang H, Hang J, Cheng P, Hai Z, Xiao S, Qian H, Xiao S, Jing X, Xie Z, Ling H, Liu L, Gao L, Deng Q, Cowling BJ, Li Y
Building and environment. 2022; 207(): 108414

A UHPLC/MS/MS method for the analysis of active and inactive forms of GLP-1 and GIP incretins in human plasma.
Villaño D, Zafrilla P, García-Viguera C, Domínguez-Perles R
Talanta. 2022; 236(): 122806

Understanding the Mechanisms of Gravity Resistance in Plants.
Soga K, Yano S, Kamada M, Matsumoto S, Hoson T
Methods in molecular biology (Clifton, N.J.). 2022; 2368(): 267-279

Genotypic Distribution and Antimicrobial Susceptibilities of Carbapenemase-Producing Isolated From Rectal and Clinical Samples in Korean University Hospitals Between 2016 and 2019.
Jeong S, Lee N, Park MJ, Jeon K, Kim HS, Kim HS, Kim JS, Song W
Annals of laboratory medicine. 2022; 42(1): 36-46

Functional Characterization of Target Genes Associated with Insecticide Resistance of the Green Peach Aphid, Myzus persicae.
Fosu-Nyarko J, Iqbal S, Brigg F, Jones MGK
Methods in molecular biology (Clifton, N.J.). 2022; 2360(): 187-208


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites